edavarone
Jump to navigation
Jump to search
Indications
- FDA-appproved as adjunctive treatment to riluzole in patients with amyotrophic lateral sclerosis (ALS)*
* may not provide any benefit to patients with ALS
Adverse effects
- seems safe
References
- ↑ Witzel S, Maier S, Steinbach R et al Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. JAMA Neurol. 2022;79(2):121-130 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35006266 PMCID: PMC8749709 (available on 2023-01-10) https://jamanetwork.com/journals/jamaneurology/fullarticle/2787473